Ping Feng1, De-min Yu2, Li-ming Chen2, Bao-cheng Chang2, Qiu-di Ji1, Shu-ying Li1, Mei Zhu1, Sheng-hua Ding3, Bao-zhen Zhang3, Su-li Wang4, Hong-tao Li5, Jing-na Lin6, Mao-jun Wang7, Jian-chao Guo8, Jie Liu9, Zhong-dong Liu9, Shen-tao Wu10, Ju-hong Yang2. 1. The General Hospital of Tianjin Medical University, Tianjin 300052, China. 2. 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Key Laboratory of Hormone and Development (Ministry of Health), Metabolic Disease Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China. 3. The Chinese PLA464 Hospital, Tianjin 300381, China. 4. Department of Endocrinology, the Affiliated Hospital of Logistics University of Chinese People's Armed Police Forces, Tianjin 300162, China. 5. Armed Police Crops Hospital, Tianjin 300162, China. 6. Tianjin People's Hospital, Tianjin 300121, China. 7. Tian Jin Shi Xian Shui Gu Hospital, Tianjin 300052, China. 8. The Second Hospital of Tianjin Medical University, Tianjin 300211, China. 9. Nankai Hospital of Traditional Chinese Medicine, Affiliated with Tianjin University of Traditional Chinese Medicine, Tianjin 300102, China. 10. The First Hospital Affiliated to Tianjin Medical University, Tianjin 300193, China.
Abstract
AIM: To investigate the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor activator, on body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. METHODS: A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study. The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments. Statistical analyses were performed using SPSS software package version 11.5 for Windows. RESULTS: Liraglutide treatment caused significant reduction of the mean body weight (from 86.61±14.09 to 79.10±13.55 kg) and waist circumference (from 101.81±13.96 to 94.29±14.17 cm), resulting in body weight lose of 5%-10% in 43.67% patients, and body weight loss above 10% in 34.06% patients, who had significant lower plasma creatinine levels. Baseline waist circumference, BMI and HOMA-IR were independently correlated with the body weight loss. Furthermore, liraglutide treatment significantly decreased HbA1c levels (from 8.66%±2.17% to 6.92%±0.95%) with HbA1c<7.0% in 35.37% patients, who had a significantly lower baseline level of HbA1c, but higher baseline levels of C peptide and glucagon. Moreover, liraglutide treatment resulted in greater body weight loss in patients with a long duration of diabetes, and better glycemic control in patients with a short duration of diabetes. CONCLUSION: Liraglutide significantly reduces body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Patients with apparent visceral obesity, insulin resistance and a long duration of diabetes may have greater body weight loss; whereas patients with high insulin-secreting ability, hyperglucagonemia, and short-duration diabetes may obtain better glycemic control with liraglutide.
AIM: To investigate the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor activator, on body weight and waist circumference in Chinese overweight and obese type 2 diabeticpatients. METHODS: A total of 328 Chinese overweight and obese type 2 diabeticpatients were included in this multi-center, open-labeled and self-controlled clinical study. The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments. Statistical analyses were performed using SPSS software package version 11.5 for Windows. RESULTS: Liraglutide treatment caused significant reduction of the mean body weight (from 86.61±14.09 to 79.10±13.55 kg) and waist circumference (from 101.81±13.96 to 94.29±14.17 cm), resulting in body weight lose of 5%-10% in 43.67% patients, and body weight loss above 10% in 34.06% patients, who had significant lower plasma creatinine levels. Baseline waist circumference, BMI and HOMA-IR were independently correlated with the body weight loss. Furthermore, liraglutide treatment significantly decreased HbA1c levels (from 8.66%±2.17% to 6.92%±0.95%) with HbA1c<7.0% in 35.37% patients, who had a significantly lower baseline level of HbA1c, but higher baseline levels of C peptide and glucagon. Moreover, liraglutide treatment resulted in greater body weight loss in patients with a long duration of diabetes, and better glycemic control in patients with a short duration of diabetes. CONCLUSION: Liraglutide significantly reduces body weight and waist circumference in Chinese overweight and obese type 2 diabeticpatients. Patients with apparent visceral obesity, insulin resistance and a long duration of diabetes may have greater body weight loss; whereas patients with high insulin-secreting ability, hyperglucagonemia, and short-duration diabetes may obtain better glycemic control with liraglutide.
Authors: S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews Journal: Diabetologia Date: 2012-04-20 Impact factor: 10.122
Authors: Jongha Park; Rajnish Mehrotra; Connie M Rhee; Miklos Z Molnar; Lilia R Lukowsky; Sapna S Patel; Allen R Nissenson; Joel D Kopple; Csaba P Kovesdy; Kamyar Kalantar-Zadeh Journal: Nephrol Dial Transplant Date: 2013-06-05 Impact factor: 5.992
Authors: Helena M de Wit; Gerald M M Vervoort; Henry J Jansen; Wim J C de Grauw; Bastiaan E de Galan; Cees J Tack Journal: Diabetologia Date: 2014-06-20 Impact factor: 10.122
Authors: Maria Mirabelli; Eusebio Chiefari; Patrizia Caroleo; Biagio Arcidiacono; Domenica Maria Corigliano; Stefania Giuliano; Francesco Saverio Brunetti; Sinan Tanyolaç; Daniela Patrizia Foti; Luigi Puccio; Antonio Brunetti Journal: Int J Environ Res Public Health Date: 2019-12-27 Impact factor: 3.390